Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD

Anne Marie Kirsten, Karin Förster, Eva Radeczky, Anneliese Linnhoff, Beatrix Balint, Henrik Watz, Heather Wray, Lynette Salkeld, Marie Cullberg, Hung Lam, Bengt Larsson
European Respiratory Journal 2012 40: 3083; DOI:
Anne Marie Kirsten
1Pulmonary Research Institute, Hospital Grosshansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Förster
2Practice for Pneumology and Cardiology, Practice for Pneumology and Cardiology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Radeczky
3MEN CARE Medical Centre, MEN CARE Medical Centre, Százhalombatta, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anneliese Linnhoff
4Practice for Lung, Bronchial, Allergy and Environmental Medicine, Practice for Lung, Bronchial, Allergy and Environmental Medicine, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beatrix Balint
5Chest Diseases Hospital, Deszk, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Watz
1Pulmonary Research Institute, Hospital Grosshansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Wray
6Research & Development, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynette Salkeld
6Research & Development, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Cullberg
6Research & Development, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hung Lam
7Research & Development, AstraZeneca, Södertälje, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bengt Larsson
6Research & Development, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

BACKGROUND: This Phase IIa study evaluated the safety and tolerability of the CXCR2 antagonist AZD5069 in patients with moderate-to-severe COPD.

METHODS: This was a 4-week, randomised, double-blind, placebo-controlled, parallel group, multi-centre study. Patients were aged 40–80 years, with a diagnosis of moderate-to-severe COPD for >1 year. Patients received placebo (PBO) bd (n=29), AZD5069 50 mg twice-daily (bd) (n=30) or AZD5069 80 mg bd (n=28) for 4 weeks. Primary safety and tolerability outcome variables included adverse events (AEs), ECG, haematology, clinical chemistry, urinalysis, vital signs, and lung function. The pharmacokinetics (PK) of AZD5069 and the effect of exposure on circulating neutrophils were assessed as secondary objectives.

RESULTS: Patients had a mean age of 64 years (69% male; all white). There were no deaths. Two SAEs (one with 50 mg and one with 80 mg) were assessed by the investigator as not related to AZD5069. The number of patients with AEs was evenly distributed across treatment groups. Discontinuation due to AEs was also similar across treatment groups, but highest in patients receiving AZD5069 50 mg (3, 5 and 2 patients receiving PBO, AZD5069 50 mg and 80 mg respectively). The PK was as predicted from healthy volunteers, but with higher variability. As expected, there was an exposure-related, reversible reduction in circulating neutrophils with AZD5069. No other clinically important changes in primary variables, including infection rates, were observed with AZD5069.

CONCLUSIONS: AZD5069 was well tolerated with no safety issues identified in this 4 week Phase IIa COPD patient trial.

  • Anti-inflammatory
  • COPD - management
  • Pharmacology
  • © 2012 ERS
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
Anne Marie Kirsten, Karin Förster, Eva Radeczky, Anneliese Linnhoff, Beatrix Balint, Henrik Watz, Heather Wray, Lynette Salkeld, Marie Cullberg, Hung Lam, Bengt Larsson
European Respiratory Journal Sep 2012, 40 (Suppl 56) 3083;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
Anne Marie Kirsten, Karin Förster, Eva Radeczky, Anneliese Linnhoff, Beatrix Balint, Henrik Watz, Heather Wray, Lynette Salkeld, Marie Cullberg, Hung Lam, Bengt Larsson
European Respiratory Journal Sep 2012, 40 (Suppl 56) 3083;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Olodaterol attenuates bleomycin induced lung fibrosis in mice
  • Monitoring local pulmonary cAMP levels: Combining precision cut lung slice (PCLS) and fluorescence resonance energy transfer (FRET) technologies in mice
  • Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society